A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline | Insights by DelveInsight
09 Jun 2021
Los Angeles, June 08, 2021 (GLOBE NEWSWIRE) -- A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline | Insights by DelveInsight
For the treatment of Chronic Spontaneous Urticaria, there are several drugs being developed by different pharmaceutical industries with different routes of administration like oral, subcutaneous, intravenous which could be chosen according to the affordability and feasibility of an individual.
DelveInsight’s ‘Chronic Spontaneous Urticaria Pipeline Insights’ report offers a holistic coverage of the current treatments and pipeline therapies and landscape in different stages of development from pre-clinical till late-stage, along with dormant, inactive and abandoned therapeutic agents.
Some of the key pointers from the Chronic Spontaneous Urticaria Pipeline report:
Request for Sample to know more about the key pharma company and therapy expected to grab maximum share @ Chronic Spontaneous Urticaria Emerging Therapies and Forecast
Chronic Spontaneous Urticaria: Overview
Chronic Urticaria (CU) is a condition of the skin caused by a plenitude of factors such as environmental irritants, your immune system, genetics, or in response to a bacterial, fungal, or viral infection. Based on the cause, it can be of two types Chronic Idiopathic Urticaria (also called chronic spontaneous urticaria) and Chronic Inducible Urticaria (also called physical urticaria).
Chronic Spontaneous Urticaria was previously referred to as Chronic Idiopathic Urticaria, however, the term is no longer used as many cases have an autoimmune basis.
For more information on emerging drugs, visit Chronic Spontaneous Urticaria Pipeline Analysis
Chronic Spontaneous Urticaria Drug Pipeline Assessment
Request for Sample to know more @ Chronic Spontaneous Urticaria Pipeline Analysis, Key Companies and Futuristic Trends
Chronic Spontaneous Urticaria Therapeutics Assessment
The Chronic Spontaneous Urticaria Pipeline report proffers comprehensive coverage of the active pipeline candidates segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
By Stage
By Molecule Type
By Route of Administration
By Mechanism of Action
By Targets
Connect with our Business Executive for Asset Prioritization Services and Consulting Solutions
Scope of the Chronic Spontaneous Urticaria Pipeline Report
Coverage: GlobalKey Players: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, GlaxoSmithKline, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, Amgen, and others. Key Chronic Spontaneous Urticaria Pipeline Therapies: UB-221, GBR 310, Ligelizumab, UCB8600, Antolimab, Dupilumab, GI-301, CDX-0159, LY3454738, Fenebrutinib, GS-4059, Nucala, SYN008, BP001, Tezepelumab and others.
Reach out @ Chronic Spontaneous Urticaria Pipeline: Novel therapies and Emerging technologies
Table of Contents
Learn more about the report offerings @ Chronic Spontaneous Urticaria Emerging Therapies, Treatments and Ongoing Clinical Trials
Related Reports
Chronic Spontaneous Urticaria MarketDelveInsight’s ‘Chronic spontaneous urticaria (CSU) – Market Insights, Epidemiology, and Market Forecast—2030’ report.
Chronic Inducible Urticaria Market ForecastDelveInsight’s ‘Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast-2030’ report.
Scleroderma MarketDelveInsight's " Scleroderma Market Insights, Epidemiology, and Market Forecast-2030" report.
Skin Neoplasms MarketDelveInsight's "Skin Neoplasms - Market Insights, Epidemiology, and Market Forecast-2030" report.
Soft Tissue Defect MarketDelveInsight's "Soft Tissue Defect - Market Insights, Epidemiology, and Market Forecast-2030" report.
Uremic Pruritus MarketDelveInsight's "Uremic Pruritus (UP) - Market Insights, Epidemiology, and Market Forecast-2030" report.
Warts MarketDelveInsight's "Warts Market Insights, Epidemiology, and Market Forecast-2030" report.
Related Posts
Highlights from ASCO20218 most common allergensDeadliest infectious diseasesChronic Hand Eczema Market Analysis and Forecast
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.